Trials / Conditions / Non-small Cell Carcinoma

Non-small Cell Carcinoma

19 registered clinical trials studyying Non-small Cell Carcinoma — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants NCT07144280	Pfizer	Phase 3
Active Not Recruiting	A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) NCT05973487	TScan Therapeutics, Inc.	Phase 1
Recruiting	Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer NCT06057766	University Hospital, Ghent	N/A
Unknown	Combining ICI With SBRT or HypoFrx-RT for ES NSCLC NCT05451173	Alexander Chi	Phase 1 / Phase 2
Terminated	A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and NCT05551117	MacroGenics	Phase 2
Recruiting	Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumou NCT05752552	DeuterOncology	Phase 1
Recruiting	A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) NCT05657873	Memorial Sloan Kettering Cancer Center	Phase 2
Completed	Investigating the Feasibility of a Physical Activity (tele)coaching Intervention in Patients with Non-small Ce NCT05569291	Hasselt University	N/A
Unknown	Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Pa NCT05319886	The First Affiliated Hospital of Xinxiang Medical College	—
Withdrawn	Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC NCT05007769	Washington University School of Medicine	Phase 2
Active Not Recruiting	Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) NCT04791839	Washington University School of Medicine	Phase 2
Active Not Recruiting	Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations NCT04695925	Li Zhang, MD	Phase 3
Active Not Recruiting	Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules NCT04171492	Biodesix, Inc.	—
Terminated	Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer NCT04364048	Rachel Sanborn	Phase 2
Recruiting	Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer NCT03991819	University Health Network, Toronto	Phase 1
Completed	A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer NCT02922764	Inspirna, Inc.	Phase 1
Completed	Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer NCT03394105	Asan Medical Center	Phase 2
Terminated	Safety Study of SEA-CD40 in Cancer Patients NCT02376699	Seagen Inc.	Phase 1
Completed	Vaccine Treatment for Advanced Non-Small Cell Lung Cancer NCT00073398	NewLink Genetics Corporation	Phase 1 / Phase 2